Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

References on malignant melanoma

    1. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD
    2. de Vires E & Coebergh JW. Cutaneous malignant melanoma in Europe. Eur J Cancer 2004; 40: 2355–66.
    3. de Vires E , Bray F, Coebergh JW in DM. Changing epidemiology of malignant cutaneous melanoma in Europe 1967–1997: rising trends in incidence and mortality, but stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 2003; 107: 119–26.
    4. Marghoob AA. Large congenital melanocytic nevi and the risk for the development of malignant melanoma. Arc Dermatol 1996; 132: 170–5.
    5. Rockley PF. Non risk factors for malignant melanoma. Chemical agents, physical conditions and occupation. Int J Dermatol 1994; 33: 398–405.
    6. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trail. JAMA 1998; 280: 1485–9.
    7. Huber MR, Markovic SN. Adjuvant nodal radiotherapy for node positive head and neck melanoma: A single institution experience. Proc Am Soc Clin Oncol 2004; 23: 716, abstract 7537
    8. Kraehn GM, Schartl M, Peter RU. Human malignant melanoma. A genetic disease? Cancer 1995; 75: 1228–37.
    9. Balch CM, Houghton AN, Milton GW et al. red. Cutaneous melanoma. 2. utg. Philadelphia: Lippincott, 1992: 165–86.
    10. Massback A, Olsson H, Westerdahl J et al. Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review. Melanoma Res 2001; 11: 435–45
    11. Seregard S. Posterior uvealt melanoma. The Swedish perspective. Acta Ophthalmol Scand 1996; 74: 315–329
    12. Handlingsprogrammet for malignt melanom 2011. Norsk Melanomgruppe
    13. Balch CM, Gershenvald JE, Soony SJ, Thompson JF, Atkins MB, Byrd DR et al. Final versjon of 2009 AJCC melanoma staging and classification. J.Clin Oncol 2009; 27 (36):  6199-206
    14. Danson SJ, Middleton MR. temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther 2001; 1: 13-9.
    15. Hodi FS, Oble DA, Drappatz J, et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 2008; 5: 557-61.
    16. Hodi FS, O`Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
    17. Kullavanijaya, P, Lim HW. Photoprotection. J Am Acad dermatol 2005, 52(6): 937-58.
    18. Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use randomized trial follow-up. J Clin Oncol 2011; 29 (3): 257-63.
    19. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers. A systematic review. Int J Cancer 2007; 120 (5): 1116-22.
    20. Eapen S, Dutcher JP. A review of evidence-based treatment of stage IIB to stage IV melanoma. Cancer Invest 2005; 23: 323-37.
    21. Verma S, Quart I, McCready et al. Systemic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006; 106: 1431-42.
    22. Tawbi HA, Kirkwood J. management of metastatic melanoma. Semin Oncol 2007; 34: 532-45.
    23. Middelton MR, Grob JJ, Aaronson N et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic  melanoma. J Clin Oncol 2000; 18: 158-66.
    24. Kadison AS, Morton DL. Immuntherapy of malignant melanoma. Surg  Clin North Am 2003; 83: 343-70.
    25. Agarwala SS, Kirkwood JM. Update on adjuvant interferon therapy for high-risk melanoma. Oncology 2002; 16: 1177-87, discussion 90-2, 97.
    26. Hamm C, verma S, Petrella T et al. Biochemotherapy for the treatment of metastatic malignant melanioma. A systematic review.Cancer Treat Rev 2008;34: 145-56.
    27. Wolchok JD, Kluger H, Callahan K et al. Nivolumab plus ipilimumab in advanced melanoma. new Engl J Med 2013; 369: 122-33.
    28. Fenig E, Eidelevich E, Njugana E, et al. Role of Radiation Therapy in the Management of Cutaneous Malignant Melanoma. Am J Clin Oncol 1999; 2: 184–6.
    29. Noel G, Simm JM, Valery C-A et al. Linac radiosurgery for brain metastasis of meloma. Stereotact Funct Neurosurg 2002; 79: 245-255. 
    30. Waldeland E, Brustugun OT, Ramberg C, Helland Å. Stereotaktisk bestråling av columnametastaser. Tidsskr Nor Lægeforen 2012; 132: 2478-9.
    31. Xing Y, Bronstein Y, Ross M, et al. Contemorary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 2011; 103 (2): 129-42.
    32. Jimenez-Requena F, Delgado-Bolton RC, Fernandez-Perez C et al. Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma. Eur J Nucl Med Mol Imaging 2010; 37(2): 284-300.
    33. Lejeune FJ, Kroon BB, Di Filippo F et al. Isolated limb perfusion: the European experience. Surg Oncol Clin N Am 2001; 10: 821-32.

    34. Ricotti F, Giuliodori K, Cataldi I et al.Electrochemotherapy: an effective local treatment of cutaneous and subcutaneous melanoma metastases. Dermatol Ther. 2014 May-Jun; 27 (3): 148-52.
    35. Queirolo P, Marincola F, Spagnolo F. Electrochemotherapy for the management of melanoma skin metastases: a review of the literature and possible combinations with immuntherapy. Arch Dermatol Res. 2014 Aug: 306(6): 521.6.

    36. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.

    37. Chapman PB, Hauschild A, Robert C. Improved survival with Vemurafenib in melanoma with BRAF V600 mutation.N Engl J Med 2011; 364: 2507-2516.

    38. Flaherty  KT,  Puzanov  I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma.N Engl j Med 2010; 363: 809-819.

    39. Mendenhal  WM, Amdur RJ, Grobmyer SR et al. Adjuvant radiotherapy for cutaneous melanoma. Cancer 2008; 112: 1189-96

Oslo University Hospital shall not be liable for any loss whether direct, indirect, incidental or consequential, arising out of access to, use of, or reliance upon any of the content on this website. Oslo University Hospital© 2017